1-17 of 17 results for subject:Arthritis
Librarians' tools
- Search time
- 0.244 seconds
- Solr query time
- 0.003 seconds
- Search query
- subject:Arthritis
- We searched for
- subject_t:Arthritis OR subject_ses:8418
Type
House
Session
Year
Department
Member
Primary member
Answering member
More
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health pursuant to her answer of 13 March 2006, Official Report, columns 2027–8W, if she will (a) collate and (b) publish information on primary care trusts which have not yet met the requirements to fund National Institute for Health and Clinical Excellence-approved anti-TNF...
To ask the Secretary of State for Health pursuant to her answer of 13 March 2006, Official Report, columns 2027–8W, if she will (a) collate and (b) publish information on primary care trusts which have not yet met the requirements to fund National Institute for Health and Clinical Excellence-approved anti-TNF...
To ask the Secretary of State for Health how much funding the Government have provided for research into treatments for those suffering from arthritis in the last five years; and if she will make a statement.
To ask the Secretary of State for Health how much funding the Government have provided for research into treatments for those suffering from arthritis in the last five years; and if she will make a statement.
| Expenditure on research(£ million) | |
| 1999–2000 | 4.8 |
| 2000–01 | 3.9 |
| 2001–02 | 4.2 |
| 2002–03 | 6.8 |
| 2003–04 | 6.8 |
(2) what assessment she has made of the potential impact of (a) existing NHS deficits on the uptake of treatment approved by the National Institute for Health and Clinical Excellence for use in rheumatoid arthritis and (b) payment by results and practice-based commissioning on the availability of these treatments; and...
(2) what assessment she has made of the potential impact of (a) existing NHS deficits on the uptake of treatment approved by the National Institute for Health and Clinical Excellence for use in rheumatoid arthritis and (b) payment by results and practice-based commissioning on the availability of these treatments; and...
To ask the Secretary of State for Health (1) which primary care trusts have not yet made available to those with a clinical need treatment approved by the National Institute for Health and Clinical Excellence for use in rheumatoid arthritis;
To ask the Secretary of State for Health (1) which primary care trusts have not yet made available to those with a clinical need treatment approved by the National Institute for Health and Clinical Excellence for use in rheumatoid arthritis;
(3) what the total budget for anti-tumour necrosis factor therapy is for 2006–07 in England;
(3) what the total budget for anti-tumour necrosis factor therapy is for 2006–07 in England;
| Cost of prescriptions dispensed for anti-TNF drugs, 2000–04 | |
|---|---|
| Cost (£) | |
| 2000 | 12,000 |
| 2001 | 198,000 |
| 2002 | 327,000 |
| 2003 | 833,000 |
| 2004 | 2,312,000 |
To ask the Secretary of State for Health (1) how anti-tumour necrosis therapy out-patients costs will be calculated under the payments by results scheme; and when procedures for purchasing anti-tumour necrosis therapy out-patient services will come into effect;
To ask the Secretary of State for Health (1) how anti-tumour necrosis therapy out-patients costs will be calculated under the payments by results scheme; and when procedures for purchasing anti-tumour necrosis therapy out-patient services will come into effect;
| Cost of prescriptions dispensed for anti-TNF drugs, 2000–04 | |
|---|---|
| Cost (£) | |
| 2000 | 12,000 |
| 2001 | 198,000 |
| 2002 | 327,000 |
| 2003 | 833,000 |
| 2004 | 2,312,000 |
(2) how much money was spent on anti-tumour necrosis therapy in England in each of the last five years;
(2) how much money was spent on anti-tumour necrosis therapy in England in each of the last five years;
| Cost of prescriptions dispensed for anti-TNF drugs, 2000–04 | |
|---|---|
| Cost (£) | |
| 2000 | 12,000 |
| 2001 | 198,000 |
| 2002 | 327,000 |
| 2003 | 833,000 |
| 2004 | 2,312,000 |
(5) how many patients are waiting to commence anti-tumour necrosis factor therapy in England.
(5) how many patients are waiting to commence anti-tumour necrosis factor therapy in England.
| Cost of prescriptions dispensed for anti-TNF drugs, 2000–04 | |
|---|---|
| Cost (£) | |
| 2000 | 12,000 |
| 2001 | 198,000 |
| 2002 | 327,000 |
| 2003 | 833,000 |
| 2004 | 2,312,000 |
(4) how many patients have received anti-tumour necrosis factor therapy in England in each of the last five years;
(4) how many patients have received anti-tumour necrosis factor therapy in England in each of the last five years;
| Cost of prescriptions dispensed for anti-TNF drugs, 2000–04 | |
|---|---|
| Cost (£) | |
| 2000 | 12,000 |
| 2001 | 198,000 |
| 2002 | 327,000 |
| 2003 | 833,000 |
| 2004 | 2,312,000 |
To ask the Secretary of State for Health what proportion of rheumatologists are unable to prescribe anti-TNFa therapy to rheumatoid patients they identify as being suitable for such treatment in accordance with National Institute for Clinical Excellence guidelines.
To ask the Secretary of State for Health what proportion of rheumatologists are unable to prescribe anti-TNFa therapy to rheumatoid patients they identify as being suitable for such treatment in accordance with National Institute for Clinical Excellence guidelines.
To ask the Secretary of State for Health, what evidence she has received from the British Society for Rheumatology relating to the prevalence of postcode prescribing in the treatment of (a) rheumatoid arthritis, (b) ankylosing spondylitis and (c) psoriatic arthritis.
To ask the Secretary of State for Health, what evidence she has received from the British Society for Rheumatology relating to the prevalence of postcode prescribing in the treatment of (a) rheumatoid arthritis, (b) ankylosing spondylitis and (c) psoriatic arthritis.
To ask the Secretary of State for Health what plans she has to ensure that the guidance from the National Institute for Clinical Excellence instructing health care trusts to provide anti-TNFa intervention to those patients with rheumatoid arthritis who qualify is followed by trusts.
To ask the Secretary of State for Health what plans she has to ensure that the guidance from the National Institute for Clinical Excellence instructing health care trusts to provide anti-TNFa intervention to those patients with rheumatoid arthritis who qualify is followed by trusts.
To ask the Secretary of State for Health if she will make a statement on availability of drugs to treat arthritis.
To ask the Secretary of State for Health if she will make a statement on availability of drugs to treat arthritis.
To ask the Secretary of State for Health if she will list the health (a) authorities and (b) trusts in England providing funding for anti-TNF therapy for people with rheumatoid arthritis; and if she will make a statement.
To ask the Secretary of State for Health if she will list the health (a) authorities and (b) trusts in England providing funding for anti-TNF therapy for people with rheumatoid arthritis; and if she will make a statement.
To ask the Secretary of State for Health (1) what action she plans to take to tackle non-compliance with National Institute for Health and Clinical Excellence guidelines on the treatment of severe rheumatoid arthritis;
To ask the Secretary of State for Health (1) what action she plans to take to tackle non-compliance with National Institute for Health and Clinical Excellence guidelines on the treatment of severe rheumatoid arthritis;
(2) what estimate she has made of the number of patients with severe rheumatoid arthritis who would benefit from anti-TNFa therapy but who do not receive it; and if she will make a statement;
(2) what estimate she has made of the number of patients with severe rheumatoid arthritis who would benefit from anti-TNFa therapy but who do not receive it; and if she will make a statement;
(3) if she will make a statement on whether anti-TNFa treatment will be made available on prescription in all areas.
(3) if she will make a statement on whether anti-TNFa treatment will be made available on prescription in all areas.